Ovulation induction in infertile patients with polycystic ovary syndrome

Minerva Ginecologica

Volumn 58, Issue 2, 2006, Pages 115-135

  Palomba, S ^a   Zullo, F ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Anovulation; Infertility; Ovulation induction; Polycystic ovary syndrome; Pregnancy

Indexed keywords

AROMATASE INHIBITOR; CLOMIFENE CITRATE; CYTOCHROME P450; DEXAMETHASONE; ESTROGEN; GONADOTROPIN; GONADOTROPIN DERIVATIVE; KETOCONAZOLE; LETROZOLE; METFORMIN; NALTREXONE; OCTREOTIDE; OPIATE ANTAGONIST; TAMOXIFEN;

ANOVULATION; DIET; DRILL; ECTOPIC PREGNANCY; ESTROGEN DEFICIENCY; HUMAN; INFERTILITY; LAPAROSCOPY; MENSTRUAL CYCLE; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PHYSICAL ACTIVITY; REVIEW; SPONTANEOUS ABORTION; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

AROMATASE INHIBITORS; CLOMIPHENE; DECISION TREES; DIET; DRUG THERAPY, COMBINATION; FEMALE; GONADOTROPINS; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; INFERTILITY, FEMALE; LIFE STYLE; METFORMIN; MOTOR ACTIVITY; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; WEIGHT LOSS;

EID: 33646547626     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (206)

1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
4. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:671-83.
5. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588-93.
6. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-701.
7. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L et al. The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2-5.
8. Zawdaki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Given JR, Haseltine F, Merriam GR editors. Polycystic Ovary Syndrome. Boston: Blackwell; 1992. p.377-84.
9. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
10. Palomba S, Orio F Jr, Russo T, Falbo A, Cascella T, Colao A et al. Is still a problem the ovulation induction in women with polycictic ovary syndrome? J Endocrinol Invest 2004;7:796-805.
11. Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004;10:267-80.
12. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005;25:391-406.
13. Laitinen J, Taponen S, Martikainen H, Pouta A, Millwood I, Hartikainen AL et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003;27:710-5.
14. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 1989;31:87-120.
15. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11.
16. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-9.
17. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-5.
18. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-4.
19. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251-7.
20. Galletly C, Clark A, Tomlinson L, Blaney F. A group program for obese, infertile women: weight loss and improved psychological health. J Psychosom Obstet Gynaecol 1996;17:125-8.
21. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-11.
22. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;61:598-604.
23. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-12.
24. Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001;16:1086-91.
25. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001;74:579-84.
26. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005;82:222S-5S.
27. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004;81:630-7.
28. Bowen J, Noakes M, Clifton PM. A high dairy protein, high-calcium diet minimizes bone turnover in overweight adults during weight loss. J Nutr 2004;134:568-73.
29. Farnsworth E, Luscombe ND, Noakes M, Wittert G, Argyiou E, Clifton PM. Effect of a high-protein, energy-restricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women. Am J Clin Nutr 2003;78:31-9.
30. Elfhag K, Rossner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. Obes Rev 2005;6:67-85.
31. Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord 2004;28:1283-90.
32. Skov AR, Toubro S, Ronn B, Holm L, Astrup A. Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. Int J Obes Relat Metab Disord 1999;23:528-36.
33. Parker B, Noakes M, Luscombe N, Clifton P. Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. Diabetes Care 2002;25:425-30.
34. Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA 1999;282:1554-60.
35. Jacobsen DJ, Donnelly JE, Snyder-Heelan K, Livingston K. Adherence and attrition with intermittent and continuous exercise in overweight women. Int J Sports Med 2003;24:459-64.
36. Andersen RE, Wadden TA, Bartlett SJ, Zemel B, Verde TJ, Franckowiak SC. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial. JAMA 1999;281:335-40.
37. Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. J Clin Endocrinol Metab 2000;85:2463-8.
38. Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care 2003;26:2977-82.
39. Park SK, Park JH, Kwon YC, Kim HS, Yoon MS, Park HT. The effect of combined aerobic and resistance exercise training on abdominal fat in obese middle-aged women. J Physiol Anthropol Appl Human Sci 2003;22:129-35.
40. Altuntas Y, Bilir M, Ucak S, Gundogdu S. Reactive hypoglycemia in lean young women with PCOS and correlations with insulin sensitivity and with beta cell function. Eur J Obstet Gynecol Reprod Biol 2005;119:198-205.
41. Mayer-Davis EJ, D'Agostino R Jr, Karter AJ, Haffner SM, Rewers MJ, Saad M et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA 1998;279:669-74.
42. Holtkamp DE, Greslin JG, Root CA, Lerner LJ. Gonadotropin inhibiting and anti-fecundity effects of chloramiphene. Proc Soc Exp Biol Med 1960;105:197-201.
43. Greenblatt RB, Barfield WE, Jugck EC, Ray AW. Induction of ovulation with MRL-41: preliminary report. J Am Med Assoc 1961;178:225.
44. Greenblatt RB. Chemical induction of ovulation. Fertil Steril 1961;12:402-4.
45. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997;3:359-65.
46. Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action-a hypothesis revisited. Fertil Steril 1984;42:331-44.
47. Beck JI, Boothroyd C, Proctor M, Farquhar C, Hughes E. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev 2005;(1):CD002249.
48. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update 1996;2:483-506.
49. Homburg R. Clomiphene citrate-end of an era? A mini-review. Hum Reprod 2005;20:2043-51.
50. McDonough PG. Re: The reincarnation of an old question. Fertil Steril 2000;74:423.
51. Dlugi AM, Laufer N, Botero-Ruiz W, DeCherney AH, Polan ML, Haseltine FP et al. Altered follicular development in clomiphene citrate versus human menopausal gonadotropin-stimulated cycles for in vitro fertilization. Fertil Steril 1985;43:40-7.
52. Randall JM, Templeton A. Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles. Fertil Steril 1991;56:465-8.
53. Gonen Y, Casper RF. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990;5:670-4.
54. Nelson LM, Hershlag A, Kurl RS, Hall JL, Stillman RJ. Clomiphene citrate directly impairs endometrial receptivity in the mouse. Fertil Steril 1990;53:727-31.
55. Li TC, Warren MA, Murphy C, Sargeant S, Cooke ID. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol 1992;99:1008-13.
56. Kolibianakis EM, Zikopulos K, Fatemi HM, Osmanagaoglu K, Evenpoel J, Van Steirteghem A et al. Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination. Reprod Biomed Online 2004;8:115-8.
57. Yagel S, Ben-Chetrit A, Anteby E, Zacut D, Hochner-Celnikier D, Ron M. The effect of ethinyl estradiol on endometrial thickness and uterine volume during ovulation induction by clomiphene citrate. Fertil Steril 1992;57:33-6.
58. Shimoya K, Tomiyama T, Hashimoto K, Moriyama A, Kawamoto A, Tokugawa Y et al. Endometrial development was improved by transdermal estradiol in patients treated with clomiphene citrate. Gynecol Obstet Invest 1999;47:251-4.
59. Gerli S, Gholami H, Manna C, Di Frega AS, Vitiello C, Unfer V. Use of ethinyl estradiol to reverse the antiestrogenic effects of clomiphene citrate in patients undergoing intrauterine insemination: a comparative, randomized study. Fertil Steril 2000;73:85-9.
60. Ben-Ami M, Geslevich Y, Matilsky M, Battino S, Weiner E, Shalev E. Exogenous estrogen therapy concurrent with clomiphene citrate: lack of effect on serum sex hormones levels and endometrial thickness. Gynecol Obstet Invest 1994;37:180-2.
61. Bateman BG, Nunley WC Jr, Kolp LA. Exogenous estrogen therapy for treatment of clomiphene citrate-induced cervical mucus abnormalities: is it effective? Fertil Steril 1990;54:577-9.
62. Kessel B, Hsueh AJ. Clomiphene citrate augments follicle stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells. Fertil Steril 1987;47:334-40.
63. London SN, Young D, Caldito G, Mailhes JB. Clomiphene citrate-induced perturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes in vivo and in vitro. Fertil Steril 2000;73:620-6.
64. Oktay K, Berkowitz P, Berkus M, Schenken RS, Brzyski RG. The re-incarnation of an old question clomid effect on oocyte and embryo? Fertil Steril 2000;73:422-3.
65. Hsu CC, Kuo HC, Wang ST, Huang KE. Interference with uterine blood flow by clomiphene citrate in women with unexplained infertility. Obstet Gynecol 1995;86:917-21.
66. Palomba S, Russo T, Orio F Jr, Falbo A, Manguso F, Sammartino A et al. Uterine effects of clomiphene in women with polycystic ovary syndrome: a prospective case-control study. Am J Obstet Gynecol 2006. In press.
67. Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F. Effects of metformin and clomiphene on ovarian vascularity in patients with polycystic ovary syndrome. Fertil Steril 2006. In press.
68. Gleicher N. Cost-effective infertility care. Hum Reprod Update 2000;6:190-9.
69. ACOG technical bulletin. Managing the anovulatory state: medical induction of ovulation. Number 197 September 1994. Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1994;47:305-12.
70. Palomba S, Orio F Jr, Falbo A, Russo T, Lombardi G, Zullo F. Are laparoscopic ovarian diathermy and gonadotropin administration the only therapeutic second-steps in clomiphene citrate-resistant women with polycystic ovary sindrome? Hum Reprod 2004;19:2682-3.
71. Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone vs human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000;(2):CD000087.
72. Bayram N, van Wely M, van Der Veen F. Recombinant FSH vs urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001;(2):CD002121.
73. Fulghesu AM, Apa R, Belosi C, Ciampelli M, Selvaggi L Jr, Cucinelli F et al. Recombinant vs urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment. Horm Res 2001;55:224-8.
74. van Wely M, Bayram N, van der Veen F, Bossuyt PM. Predicting ongoing pregnancy following ovulation induction with recombinant FSH in women with polycystic ovary syndrome. Hum Reprod 2005;20:1827-32.
75. Hughes E, Collins J, Vandekerckhove P. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome. Cochrane Database Syst Rev 2000;(2):CD000097.
76. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles Cochrane Database Syst Rev 2000;(2):CD001299.
77. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279-90.
78. Olivennes F, Ayoubi JM, Fanchin R, Rongieres-Bertrand C, Hamamah S, Bouchard P et al. GnRH antagonist in single-dose applications. Hum Reprod Update 2000;6:313-7.
79. Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist centrorelix: a review. Hum Reprod Update 2000;6:322-31.
80. Elkind-Hirsch KE, Webster BW, Brown CP, Vernon MW. Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003;79:603-7.
81. Daya S. Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev 2000;(2):CD000061.
82. Franks S, Roberts R, Hardy K. Gonadotrophin regimens and oocyte quality in women with polycystic ovaries. Reprod Biomed Online 2003;6:181-4.
83. Guido M, Belosi C, Selvaggi L, Lattanzi F, Apa R, Fulghesu AM et al. The effect of age on the ovarian response to gonadotropin and on pregnancy rate in polycystic ovary syndrome. Gynecol Endocrinol 2003;17:215-21.
84. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:13-21.
85. Coffler MS, Patel K, Dahan MH, Malcom PJ, Kawashima T, Deutsch R et al. Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:1742-7.
86. st century? Hum Reprod 1998;13:2361-2.
87. Quigley MM, Schmidt CL, Beauchamp PJ, Pace-Owens S, Berkowitz AS, Wolf DP. Enhanced follicular recruitment in an in vitro fertilization program: clomiphene alone versus a clomiphene/human menopausal gonadotropins combination. Fertil Steril 1984;42:25-33.
88. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
89. Donesky BW, Adashi EY. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. Fertil Steril 1995;63:439-63.
90. Stein IF. Duration of fertility following ovarian wedge resection: Stein-Leventhal syndrome. West J Surg Obstet Gynecol 1964;72:237-42.
91. Adashi EY, Rock JA, Guzick D, Wentz AC, Jones GS, Jones HW Jr. Fertility following bilateral ovarian wedge resection: a critical analysis of 90 consecutive cases of the polycystic ovary syndrome. Fertil Steril 1981;36:30-5.
92. Buttram VC Jr, Vaquero C. Postovarian wedge resection adhesive disease. Fertil Steril 1975;26:874-6.
93. Campo S, Garcea N, Caruso A, Siccardi P. Effect of celioscopic ovarian wedge resection in patients with polycystic ovaries. Gynecol Obstet Invest 1983;15:213-22.
94. Portuondo J, Melchor J, Neyro J, Alegrea A. Periovarian adhesions following ovarian wedge resections or laparoscopic biopsy. Endoscopy 1984;16:143-5.
95. Mc Laughlin DS. Evaluation of adhesion reformation by early second-look laparoscopy following microlaser ovarian wedge resection. Fertil Steril 1984;42:531-7.
96. Palomba S, Zullo F, Diamanti-Kandarakis E, Orio F Jr. Treatment of infertility in PCOS: surgery and laser diathermy. In: Nestler JE, Diamanti-Kandarakis E, Pasquali R, Panidis D editors. Insulin resistance and polycystic ovary syndrome, evaluation, and treatment. London: The Human Press Inc; 2006.p.67-81.
97. Tulandi T. Laparoscopic treatment of polycystic ovarian syndrome. In: Tulandi T editor. Atlas of laparoscopic and hysteroscopic techniques for gynecologists. London: WB Saunders; 1999.p.93-5.
98. Gomel V, Yarali H. Surgical treatment of polycystic ovary syndrome associated with infertility. Reprod Biomed Online 2004;9:35-42.
99. Gjonnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984;41:20-5.
100. Gjonnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Acta Obstet Gynaecol Scand 1994;73:407-12.
101. Cohen J. Laparoscopic procedures for treatment of infertility related to polycystic ovarian syndrome. Hum Reprod Update 1996;2:337-44.
102. Dabirashrafi H. Complications of laparoscopic ovarian cauterization. Fertil Steril 1989;52:878-9.
103. Kovacs GT. Endoscopic surgical approach to the treatment of anovulation due to polycystic ovary syndrome-ovarian drilling. In: Sutton C, Diamond MP editors. Endoscopic Surgery for Gynaecologists. London: WB Saunders Company Ltd; 1993.p.147-53.
104. Balen J, Jacobs HS. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome. Fertil Steril 1994;5:921-5.
105. Amer SA, Li TC, Cooke ID. Laparoscopic ovarian diathermy in women with polycystic ovarian syndrome: a retrospective study on the influence of the amount of energy used on the outcome. Hum Reprod 2002;17:1046-51.
106. Malkawi HY, Qublan HS. Laparoscopic ovarian drilling in the treatment of polycystic ovary syndrome: how many punctures per ovary are needed to improve the reproductive outcome? J Obstet Gynaecol Res 2005;31:115-9.
107. Greenblatt E, Casper RF. Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fertil Steril 1993;60:766-70.
108. Pirwany I, Tulandi T. Laparoscopic treatment of polycytic ovaries: is it time to relinquish the procedure? Fertil Steril 2003;80:241-51.
109. Naether OG, Baukloh V, Fischer R, Weise HC, Geiger-Kotzler L, Delfs T et al. Laparoscopic electrocoagulation of the ovarian surface in infertile patients with polycystic ovarian disease. Fertil Steril 1993;60:88-94.
110. Saravelos H, Li TC. Postoperative adhesions after laparoscopic electrosurgical treatment for polycystic ovarian syndrome with the application of Interceed to one ovary: a prospective randomized controlled study. Hum Reprod 1996;11:992-7.
111. Amer SA, Banu Z, Li TC, Cooke ID. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: clinical outcome. Hum Reprod 2002;17:2035-42.
112. Naether OGJ, Baukloh V, Fischer R, Kowalczyk T. Long-term follow-up in 206 infertility patients with polycystic ovarian syndrome after laparoscopic electrocautery of the ovarian surface. Hum Reprod 1994;9:2342-9.
113. Gjonnaess H. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril 1998;69:697-701.
114. Elting MW, Korsen TJM, Rekers-Mombarg LTM, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-8.
115. Felemban A, Tan SL, Tulandi T. Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. Fertil Steril 2000;73:266-9.
116. Homburg R, Armar NA, Eshel A, Adams JM, Jacobs HS. Influence of serum luteinizing hormone concentrations of ovulation, conception and early pregnancy loss in polycystic ovary syndrome. BMJ 1988;297:1024-6.
117. Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC et al. Recurrent early miscarriage and polycystic ovaries. BMJ 1988;297:1027-8.
118. Abdel Gadir A, Mowa R, Alnaser H, Alrashid A, Alonezi O, Shaw R. Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clin Endocrinol 1990;33:585-92.
119. Rimington MR, Walker SM, Shaw RW. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod 1997;12:1443-7.
120. Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P. Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2005;(3):CD001122.
121. Palomba S, Orio F Jr, Falbo A, Russo T, Caterina G, Manguso F et al. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. Clin Endocrinol (Oxf.) 2005;63:631-5.
122. Aakvaag A, Gjonnaess H. Hormonal response to electrocautery of the ovary in patients with polycystic ovarian disease. Br J Obstet Gynaecol 1985;92:1258-64.
123. Colacurci N, Zullo F, De Franciscis P, Mollo A, De Placido G. in vitro fertilization following laparoscopic ovarian diathermy in women with polycistic ovarian syndrome. Acta Obstet Gynecol Scand 1997;76:555-8.
124. Tozer AJ, Al-Shawaf T, Zosmer A, Hussain S, Wilson C, Lower AM et al. Does laparoscopic ovarian diathermy affect the outcome of IVF-embryo transfer in women with polycystic ovarian syndrome? A retrospective comparative study. Hum Reprod 2001;16:91-5.
125. Amer SA, Li TC, Ledger WL. Ovulation induction using laparoscopic ovarian drilling in women with polycystic ovarian syndrome: predictors of success. Hum Reprod 2004;19:1719-24.
126. Lemieux S, Lewis GF, Ben-Chetrit A, Steiner G, Greenblatt EM. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab 1999;84:4278-82.
127. Saleh A, Morris D, Tan SL, Tulandi T. Effects of laparoscopic ovarian drilling on adrenal steroids in polycystic ovary syndrome patients with and without hyperinsulinemia. Fertil Steril 2001;75:501-4.
128. Stegmann BJ, Craig HR, Bay RC, Coonrod DV, Brady MJ, Garbaciak JA Jr. Characteristics predictive of response to ovarian diathermy in women with polycystic ovarian syndrome. Am J Obstet Gynecol 2003;188:1171-3.
129. Palomba S, Falbo A, Orio F Jr, Russo T, Sbano F, D'Alessandro P et al. Efficacy of laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: relationships with chronological and ovarian age. Gynecol Endocrinol 2006. In press.
130. Bayram N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004;328:192.
131. van Wely M, Bayram N, van der Veen F, Bossuyt PM. An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod 2004;19:1741-5.
132. Palomba S, Orio F Jr, Nardo LG, Falbo A, Russo T, Corea D et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4801-9.
133. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
134. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54.
135. Velazquez EM, Acosta A, Mendoza S. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392-5.
136. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13.
137. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-3.
138. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004;19:2474-83.
139. Norman RJ. Editorial: Metformin-comparison with other therapies in ovulation induction in polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4797-800.
140. Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Tolino A et al. Prospective parallel randomized double-blind double-dummy controlled clinical trial comparing clomiphene citrate and metformin as first-line treatment for ovulation induction in non-obese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4068-74.
141. Palomba S, Falbo A, Orio F Jr, Manguso F, Russo T, Cascella T et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006;21:457-65.
142. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-9.
143. Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double blinded placebo-controlled trial. Hum Reprod 2001;16:1625-31.
144. Maciel GA, Soares Junior Jr, Alves Da Motta EL, Abi Haidar M, De Lima AR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-60.
145. Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alverez M. Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online 2005;10:100-4.
146. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057-62.
147. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
148. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-30.
149. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-9.
150. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006;21:80-9.
151. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuccu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol 2005;123:204-11.
152. Fulghesu AM, Villa P, Pavone V, Guido M, Apa R, Caruso A et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:644-8.
153. Dale PO, Tanbo T, Haug E, Abyholm T. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod 1998;13:567-70.
154. Rice S, Christoforidis N, Gadd C, Nikolaou D, Sedani L, Donaldson A et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005;20:373-81.
155. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72:282-5.
156. Yarali H, Yildiz BO, Demirol A, Zeyneloglu HB, Yigit N, Bukulmez O et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002;17:289-94.
157. Palomba S, Falbo A, Orio F Jr, Manguso F, Russo T, Tolino A et al. A randomized controlled trial evaluating metformin pretreatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 2005;20:2879-86.
158. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001;75:505-9.
159. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Impact of metformin therapy on ovarian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing in-vitro fertilization. Reprod Biomed Online 2002;5:112-6.
160. Fedorcsak P, Dale PO, Storeng R, Abyholm T, Tanbo T. The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecol Endocrinol 2003;17:207-14.
161. Kjotrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome: a prospective, randomized, double blind study. Hum Reprod 2004;19:1315-22.
162. Onalan G, Pabuccu R, Goktolga U, Ceyhan T, Bagis T, Cincik M. Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertil Steril 2005;84:798-801.
163. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990;33:2933-42.
164. Akhtar M, Njar VC, Wright JN. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J Steroid Biochem Mol Biol 1993;44:375-87.
165. Palter SF, Tavares AB, Hourvitz A, Veldhuis JD, Adashi EY. Are estrogens of import to primate/human ovarian folliculogenesis? Endocr Rev 2001;22:389-424.
166. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999;84:2951-6.
167. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622-9.
168. Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992;13:641-69.
169. Mitwally MF, Casper RF. Aromatase inhibitors for the treatment of infertility. Expert Opin Investig Drugs 2003;12:353-71.
170. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005;192:381-6.
171. Mitwally MFM, Casper RF. The use of aromatase inhibitor for induction of ovulation in cases of clomiphene citrate failure. Curr Opin Obstet Gynecol 2002;14:255-63.
172. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305-9.
173. Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2004;85:289-91.
174. Fisher SA, Reid RL, Van Vugt DA, Casper RF. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 2002;78:280-5.
175. Fatemi HM, Kalibianakis E, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Clomiphene citrate vs letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online 2003;7:543-6.
176. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004;11:406-15.
177. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003;18:1588-97.
178. Healey S, Tan SL, Tulandi T, Biljan MM. Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil Steril 2003;80:1325-9.
179. Sammour A, Bijan MM, Tan SL, Tulandi T. Prospective randomised trial comparing the effects of letrazole (LE) and clomiphene citrate (CC) on follicular development, endometrial thickness and pregnancy rate in patients undergoing superovulation prior to intrauterine insemination (IUI). Fertil Steril 2001;76 Suppl 1:S110.
180. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004;82:1561-3.
181. Ryan GL, Moss V, Davis WA, Sparks AE, Dokras A, Van Voorhis BJ. Oral ovulation induction agents combined with low-dose gonadotropin injections and intrauterine insemination: cost- and clinical effectiveness. J Reprod Med 2005;50:943-50.
182. Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 2002;77:776-80.
183. Goswami SK, Das T, Chattopadhyay R, Sawhney V, Kumar J, Chaudhury K et al. A randomized single blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 2004;19:2031-5.
184. Garcia-Velasco JA, Moreno L, Pacheco A, Guillen A, Duque L, Requena A et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005;84:82-7.
185. Mitwally MF, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertil Steril 2005;83:229-31.
186. Cortinez A, De Carvalho I, Vantman D, Gabler F, Iniguez G, Vega M. Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertil Steril 2005;83:110-5.
187. Bayram N, van Wely M, van Der Veen F. Pulsatile luteinising hormone releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2004;(2):CD000412.
188. Gill S, Taylor AE, Martin KA, Welt CK, Adams JM, Hall JE. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2428-36.
189. Grana-Barcia M, Liz-Leston J, Lado-Abeal J. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study. Fertil Steril 2005;83:1466-72.
190. Fulghesu AM, Ciampelli M, Belosi C. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study. J Endocrinol Invest 2001;24:483-90.
191. Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril 2002;77:936-44.
192. Vanky E, Kjotrod SB, Maesel A, Bjerve KS, Carlsen SM. Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. Fertil Steril 2004;81:459-62.
193. Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepi-androsterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril 2002;78:1001-4.
194. Vanky E, Salvesen KA, Carlsen SM. Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. Hum Reprod 2004;19:529-33.
195. Keay SD, Lenton EA, Cooke ID, Hull MG, Jenkins JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadotrophins leading to a reduction in cycle cancellation rate in a standard IVF programme. Hum Reprod 2001;16:1861-5.
196. Bider D, Hourvitz A, Tur Kaspa I, Dirnfeld M, Dor J. Dexamethasone supplementation to gonadotropin stimulation for in vitro fertilization in polycystic ovarian disease. J Assist Reprod Genet 1999;16:233-5.
197. Bracero N, Zacur HA. Polycystic ovary syndrome and hyperprolactinemia. Obstet Gynecol Clin North Am 2001;28:77-84.
198. Parsanezhad ME, Alborzi S, Jahromi BN. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Int J Fertil Womens Med 2002;47:272-7.
199. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod 2001;16:2263-6.
200. Ali Hassan H, El-Gezeiry D, Nafaa TM, Baghdady I. Improved responsiveness of PCOS patients to clomiphene after CYP17a inhibitor. J Assist Reprod Genet 2001;18:608-11.
201. Parsanezhad ME, Alborzi S, Pakniat M, Schmidt EH. A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome. Fertil Steril 2003;80:1151-5.
202. Fulghesu AM, Lanzone A, Andreani CL, Pierro E, Caruso A, Mancuso S. Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertil Steril 1995;64:703-8.
203. Piaditis GP, Hatziioanidis AH, Trovas GP, Misichronis GS, Kounadi TG, Devetzaki OA et al. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45:595-604.
204. Gambineri A, Patton L, De Iasio R, Cantelli B, Cognini GE, Filicori M et al. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:3854-62.
205. Muenstermann U, Kleinstein J. Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction. Hum Reprod 2000;15:2526-30.
206. Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F. Peripheral insulin sensitivity in normal-weight not insulin-resistant women with polycystic ovary syndrome treated with metformin during its long-term administration and after its suspension. J Clin Endocrinol Metab 2006. In press.